Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-01-03
1997-04-15
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
544350, 544257, 514252, A61K 31495, A61K 3150
Patent
active
056209789
ABSTRACT:
Disclosed is a method of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma or hypoglycemia. The method comprises administering to an animal a compound of the formula: ##STR1## or a pharmaceutically acceptable salt thereof; wherein n is zero or 1; R.sup.4, R.sup.5, R.sup.6 are independently hydrogen, nitro, amino, halo, haloalkyl, cyano, alkyl, cycloalkyl, alkenyl, alkynyl, azido, acylamino, alkylsulfonyl, aryl, substituted aryl, heteroaryl, alkoxy, trialkylsilyl-substituted alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, a heterocyclic group, a heterocyclicoxy group, aralkoxy, or haloalkoxy; and R.sup.c and R.sup.d are defined in the specification. These compounds have high binding to the glycine site of the NMDA receptor.
REFERENCES:
patent: 5055465 (1991-10-01), Davey
patent: 5283244 (1994-02-01), Sakamoto et al.
patent: 5424311 (1995-03-01), Billhardt-Troughton et al.
Bigge, C.F. and Boxer, P.A., "Neuronal Cell Death and Strategies for Neuroprotection," Ann. Rep. Med. Chem. 29:13-22 (1994).
Kaye, I.A., "Some Substituted Pyrido(2,3)pyrazines," J. Med. Chem. 7:240-241 (1964).
Kessler et al., "A Glycine Site Associated with N-Methyl-D-Aspartic Acid Receptors: Characterization and Identification of a New Class of Antagonists," J. Neurochem. 52(4):1319-1328 (1989).
Kulagowski et al., "3'-(Arylmethyl)- and 3'-(Aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: Orally Active Antagonists of the Glycine Site on the NMDA Receptor," J. Med. Chem. 37:1402-1405 (1994).
Leeson, P.D., "Glycine-Site N-Methyl-D-Aspartate Receptor Antagonists," in: Drug Design for Neuroscience Kozikowski, A.P., Ed., Raven Press, pp. 339-381 (1993).
Leeson, P.D. and Iverson, L.L., "The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential," J. Med. Chem. 37(24):4053-4067.
Monn, J.A. and Schoepp, D.D., "Recent Progress in Excitatory Amino Acid Research," Annual Reports in Medicinal Chemistry 29:53-64 (1994).
Sakamoto et al., "Preparation of diketopiperazines as glutamate receptor antagonists," Chem. Abstracts 117:695 Abstracts No. 251367d (1992).
Winterfeld, K. and Wildersohn, M., "2,3-Dichlor- und 2,3,7-Trichlor-5-aza-chinoxalin," Archiv der Pharmazie 303(1):44-48 (1970).
Albert, A., et al., "Pteridine Studies. VIII. Degradation of Pteridine. Methylation of the Hydroxypteridines and Degradation of the Products," Chem. Abstr. 51(2):1977b (1960).
Albert, A., et al., "Pteridine Studies. X. Pteridines With More Than One Hydroxy or Amino Group," Chem. Abstr. 51(2):6654c (1960).
Albert, A., et al., "Pteridine Studies. Part XXXV. The Structure of the Hydrated Dimer Formed by the Action of Dilute Acid on 4-Methylpteridine," J. Chem. Soc. (C):1181-1187 (1968).
Boutte, D., et al., " Etude des Mono et Dihydroxy-pyrido-[2.3-b] et [3.4-b] Pyrazines et Synth ese de la Dioxo-1.4 T etrahydro-1.2.3.4 Pyrido-[2'.3':5.6] Pyrazino-[2.3-d] Pyridazine," C.R. Acad. Sc. Paris, Ser. C. 273(23:1645-1648 (1971).
Clark, J., et al., "Heterocyclic Studies. Part VIII. 2-Phenylpteridine and Some Related Compounds," J. Chem. Soc. (C):1408-1412 (1969).
Clark, J., and Murdoch, P.N.T., "Heterocyclic Studies. Part X. 4-Phenylpteridine and Some Methyl Derivatives," J. Chem. Soc. (C):1883-1886 (1968).
Gottlieb, R., and Pfleiderer, W., "Synthese und Elektrochemisches Verhalten von 6,7-Dioxotetrahydropteridinen und 2,3-Dioxotetrahydropyrido-pyrazinen," Chem. Ber. 111(5):1763-1779 (1978).
McFarlane, M.D., and Smith, D.M., "A New Route to N-Hydroxyquinoxaline-2,3-Diones and Some Aza-Analogues," Tetrahedron Lett. 28(50):6363-6366 (1987).
Pfleiderer, W., and Lohrmann, R., "Pteridines. XV. Synthesis of 2-Amino-4-alkoxy-7-oxodihydropteridines," Chem. Abstr. 56(5):4752b (1962).
Weinstock, J., and Dunoff, R.Y., "Pteridines. IX. Some Pteridine Isomers of Triamterene," J. Med. Chem. 11(3):565-568 (1968).
Boast, C. A. et al., "The N-methyl-D-aspartate antagonists CGS 19755 and CPP reduce ischemic brain damage in gerbils," Brain Res. 442:345-348 (1988).
Brady, K. T. et al., "Stereoisomers of N-Allylnormetazocine: Phencyclidine-Like Behavioral Effects in Squirrel Monkeys and Rats," Science 215:178-180 (1982).
Burton, D. E. et al., "Halogeno-O-phenylenediamines and Derived Heterocycles. Part I. Reductive Fission of Benzotriazoles to O-Phenylenediamines," J. Chem. Soc. (C):1268-1280 (1968).
Choi, D. W. et al., "Glutamate Neurotoxicity in Cortical Cell Culture," J. Neurosci. 7(2):357-368 (1987).
Church, J. et al., "Ketamine and MK-801 as Neuroprotective Agents in Cerebral Ischemia/Hypoxia," in: Sigma and Phenycylidine-Like Compounds as Molecular Probes in Biology, Domino, E. F. et al., eds., NPP Books: Ann Arbor pp. 747-756 (1988).
Colllins, R. C., "Selective Vulnerability of Brain: New Insights from the Excitatory Synapse," Metabolic Brain Dis. 1(4):231-240 (1986).
Collins, R. C. et al., "Selective Vulnerability of the Brain: New Insights into the Pathophysiology of Stroke," Ann. Internal Med. 110:992-1000 (1989).
Daines, R. A. et al., "Trisubstituted Pyridine Leukotriene B.sub.4 Receptor Antagonists: Synthesis and Structure-Activity Relationships," J. Med. Chem. 36(22):3321-3332 (Nov. 1993).
Decker, T. and M.-L. Lohmann-Matthes, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," J. Immunol. Meth. 15:61-69 (1988).
Dickenson, A. H. and E. Aydar, "Antagonism at the glycine site on the NMDA receptor reduces spinal nociception in the rat," Neurosci. Lett. 121:263-266 (1991).
Dubuisson, D. and S. G. Dennis, "The Formalin Test: A Quantitative Study of the Analgesic Effects of Morphine, Meperidine, and Brain Stem Stimulation in Rats and Cats," Pain 4:161-174 (1977).
Fletcher, E. J. et al., "Involvement of Glycine in Excitatory Neurotransmission," in: Glycine Neurotransmission, Ottersen, O. P. et al., eds., John Wiley and Sons, Ltd: Somerset, New Jersey (1990).
Fletcher, E. J. and D. Lodge, "Glycine reverses antagonism of N-methyl-D-aspartate (NMDA) by 1-hydroxy-3-aminopyrrolidone-2 (HA-966) but not by D-2-amino-5-phophonovalerate (D-AP5) on rat cortical slices," Eur. J. Pharm. 151:161-162 (1988).
Gill, R. et al., "Systemic Administration of MK-801 Protects Against Ischemia-Induced Hippocampal Neurodegeneration in the Gerbil," J. Neurosci. 7(10):3343-3349 (1987).
Globus, M. Y.-T. et al., "Comparative Effects of Transient Global Ischemia on Extracellular Levels of Glutamate, Glycine, and .gamma.-Aminobutyric Acid in Vulnerable and Nonvulnerable Brain Regions in the Rat," J. Neurochem. 57(2):470-478 (1991).
Gray, N. M. et al., "Novel Indole-2-carboxylates as Ligands for the Strychnine-Insensitive N-Methyl-D-aspartate-Linked Glycine Receptor," J. Med. Chem. 34:1283-1292 (1991).
Haley, J. E. et al., et al., "Evidence for spinal N-Methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat," Brain Res. 518:218-226 (1990).
Huettner, J. E. and B. P. Bean, "Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: Selective binding to open channels," Proc. Natl. Acad. Sci. 85:1307-1311 (1988).
Huidobro, F. et al., "Studies on Tolerance Development to Single Doses of Morphine in Mice," J. Pharmacol. Exp. Ther. 198(2):318-329 (1976).
Hunger, A. et al., "1-Aninoalkyl-7-azabenzimidazoles," Chem. Abs. 63:14876 (1965).
Israel, M. and A. R. Day, "Preparation of Pyrido-(2,3)-pyrazines, Pyrido-(3,4)-pyrazines and Imidazo-(b)-pyridines," J. Org. Chem. 24:1455-1460 (1959).
Johnson, J. W. and P. Ascher, "Glycine potentiates the NMDA response in cultured mouse brain neurons," Nature 325:529-531 (1987).
Jones, B. J. et al., "The potential anxiolytic activity of GR38032F, a 5-HT.sub.3 -receptor antagonist," Br. J. Pharmacol. 93:985-993 (1988).
Keana, J. F. W. et al., "Synthesis and cheracterization of a series of diarylguanidines that are noncompetitive N-methyl-D-aspartate receptor antagonists with neuroprotective properties," Proc. Natl. Acad. Sci. USA 86:5631-5635 (1989).
Kemp, J. A. et al., "7-Chlorokynurenic acid is a selective antagonist at the glycine modula
Cai Sui X.
Keana John F. W.
Weber Eckard
ACEA Pharmaceuticals, Inc.
Grumbling Matthew V.
Shah Mukund J.
State of Oregon acting by and through The Oregon State Board of
The Regents of the University of California
LandOfFree
8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-360938